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The major ophthalmic diseases of public health concern in the UK are cataract, glaucoma, diabetic 29 
retinopathy (DR) and age-related macular degeneration (AMD).1 30 
Older age is a major risk factor for each of these conditions, and expansion of treatment options has 31 
increased the resource allocation necessary per case. Hence with the number of UK residents aged 32 
over 75 set to rise from 4.9 million (2010) to 8.9 million (2035), whilst the ratio of working age to 33 
retirement age populations drops from 3.16 (2010) to 2.87 (2035),2 there is a pressing national need 34 
for proactive service provision planning to avoid a serious and progressive under-provision which 35 
cannot be ethically dealt with by continued recruitment of medical staff from nations with greater 36 
human resource problems than the UK.3,4 37 
Planning expansion of services cannot occur without estimation of future demands. We attempted 38 
epidemiological modelling, therefore, to quantify the proportional disease burden growth 2015-35 39 
in so far as that growth is driven by prevalence. In doing so, however, the constraints were as 40 
apparent as the possibilities.  41 
Epidemiological modelling – more caveat than confidence? 42 
Projections of UK population growth by Office for National Statistics (ONS) are stratified by age and 43 
gender. However, with significant variation in disease prevalence between different ethnicities5,6 and 44 
major UK ethnographic changes expected,7 modelling must incorporate ethnicity. ‘ETHPOP’ 45 
population projections for 12 ethnic groups by age and gender, constrained to ONS projections to 46 
2051, have been produced using a cohort-component model.8,9 For example, ETHPOP predicts 47 
Asian/British Asian population aged >80 to quadruple from ~60 000 in 2015 to 231 000 in 2035. 48 
Difficulties then arise, starting with the absence of contemporary UK population-based survey data 49 
to provide prevalence estimates. Increasingly historic survey data from geographically and 50 
genetically disparate contexts was, of necessity, therefore utilised. Furthermore, modelling should 51 
take into account age-specific incidence and the effects of becoming a “case” on life expectancy. 52 
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Lack of data to permit quantification of the current impact of diagnosis on life expectancy prevents 53 
serious consideration of such an approach.  54 
Other known risk factors such as smoking, hypertension, socio-economic status and obesity are not 55 
static within the UK population – but modelling to include the expected changes in these factors and 56 
their interactions with disease burden is fraught with difficulties; changes in efficacy of treatment 57 
modalities for diseases or their risk factors is impossible to predict. 58 
The undeniable size of these obstacles to the generation of academically robust projections of 59 
disease burden, does not diminish the equally undeniable need for long term service delivery 60 
planning – which cannot occur in the absence of some attempt to quantify the future needs. 61 
With this in mind, we searched for the most relevant survey data and applied them to the ETHPOP 62 
population projections via the National Eye Health Epidemiological Model (NEHEM) which facilitates 63 
application of disease prevalence to populations (www.eyehealthmodel.org).  64 
Glaucoma – Published UK Asian population studies10 cannot be considered widely representative of 65 
UK Asian/British Asian populations so meta-analysis of large studies from both India and Bangladesh 66 
was selected.6 No relevant UK Black population data is available, so meta-analysis was again used 67 
with the largest contributing studies utilising West Indies,11 USA12 and African data.13 The largest 68 
White UK population data were felt to be too old, coming from a survey undertaken in 1995/96,14 so 69 
large American, European and Australian surveys were accessed.6 Using these data, a 49% rise in 70 
glaucoma cases from 2015-35 is predicted.  71 
AMD – Prevalence data for AMD could be taken from UK sources,15 however, case definition 72 
limitations and restriction to age >75 made multicentre EUREYE data appear most representative.16 73 
The lower prevalence of blinding AMD seen in black populations was accommodated by application 74 
of data from the American Eye Diseases Prevalence Research Group.17 Using these data, a 64% rise 75 
in nAMD cases from 2015-35 is predicted.  76 
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Cataract - Absence of internationally agreed case definition, to which prevalence estimates are 77 
extremely sensitive, makes estimation of case numbers of limited value. Proportional increase in 78 
those numbers, however, is potentially very useful.  Estimates from two surveys were taken,18,19 and 79 
using these data, a 52% rise in cataract cases is expected from 2015-35. 80 
Diabetic Retinopathy - The global diabetic population by 2030 has been variously predicted to rise by 81 
three separate academic groups to; 366 million,20 439 million,21 and 552 million22. Similarly, two 82 
1997 estimates of growth rate of UK diabetic population were 4.1% annually23 and 1.0% annually.24  83 
The general scarcity and need for data and future projections to inform ophthalmic public health 84 
planning for DR is acknowledged.25 Despite this need, we concluded that the data did not exist to 85 
permit us to attempt this, as the variation in existing projections demonstrates. 86 
However, if the best indicator of future behaviour is past behaviour, then we should note that UK 87 
diabetes prevalence increased from 2.8% (1996) to 4.3% (2005), >50% rise in 10 years, hence it 88 
would seem prudent to anticipate a substantial increase in demand from DR.26 The scale of this may 89 
be similar to the predicted 86% rise in the diabetic population projected for the USA (2009-2034)27 90 
or for Germany of a 64% rise in diagnosed type 2 diabetics.28 91 
Of what value are these estimates? 92 
If a large, unquantified and changing proportion of glaucoma is undiagnosed, and visual thresholds 93 
for cataract surgery alter surgical numbers far more than prevalence, then it would be reasonable to 94 
assert that predicting numbers of “cases” in a population has little to offer to service planning and 95 
that the case numbers in table 1 can be discounted. However, there must be a substantial 96 
proportion of demand that is driven by prevalence, and in so far as the conversion rate between 97 
prevalence and demand remains relatively stable, epidemiological modelling gives the best chance 98 
of estimating by what proportion demand will rise. 99 
  100 
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The historic lack of prospective planning for rising demand has allowed a capacity shortfall with well-101 
documented national level evidence of harm to patients.29,30 Short term financial targets make it 102 
unattractive for managers to configure services with any excess capacity to accommodate expected 103 
growth, hence utilisation of inefficient short term fixes such as waiting list initiatives, until the 104 
system decompensates with serious untoward incidents at which point investment to increase 105 
routine capacity becomes unavoidable. This situation must change. 106 
 107 
Better source data for planning would require a UK national population-based survey, but until this 108 
becomes available, these estimates of proportional increase in case numbers offer some guidance 109 
on the size of the growth in service delivery that UK eye care services will be expected to deliver 110 
over the next 20 years – and as such should be useful to those taking the long view nationally or 111 
locally on resource allocation and workforce planning. Amongst the uncertainties, one thing can be 112 
said for sure: if we fail to plan for growth, we are consciously planning to fail our patients in the 113 
years to come.  114 
 115 
  116 
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Table 1: Estimated and projected numbers of cases of Glaucoma, Cataract and nAMD in the UK 117 
2015-2035 118 
 
Glaucoma Cases 
(% increase cf 2015)  
Cataract Cases 
(% increase cf 2015) 
nAMD Cases 
(% increase cf 2015) 
2015 659 000 
 
- 1 450 000 
 
- 411 000 
 
- 
2025 807 000   23% 1 790 000 23% 521 000 27% 
2035 983 000 49% 2 210 000 52% 672 000 64% 
 119 
  120 
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